Brief: Nabriva Receives European Approval For XENLETA(Lefamulin) For Treatment Of Community-Acquired Pneumonia (CAP)
28/07/2020 18:52
July 28 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA RECEIVES EUROPEAN APPROVAL FOR XENLETA®
(LEFAMULIN) FOR
TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Source text for Eikon: ID:nGNX37v406
Further company coverage: NBRV.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update